WO1994003467A3 - Antiretroviral enantiomeric nucleotide analogs - Google Patents

Antiretroviral enantiomeric nucleotide analogs Download PDF

Info

Publication number
WO1994003467A3
WO1994003467A3 PCT/US1993/007360 US9307360W WO9403467A3 WO 1994003467 A3 WO1994003467 A3 WO 1994003467A3 US 9307360 W US9307360 W US 9307360W WO 9403467 A3 WO9403467 A3 WO 9403467A3
Authority
WO
WIPO (PCT)
Prior art keywords
antiretroviral
nucleotide analogs
enantiomeric nucleotide
enantiomeric
aza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/007360
Other languages
French (fr)
Other versions
WO1994003467B1 (en
WO1994003467A2 (en
Inventor
Antonin Holy
Hana Dvorakova
Erik Desire Alice Declercq
Jan Marie Rene Balzarini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Rega VZW
Gilead Sciences Inc
Original Assignee
Stichting Rega VZW
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP93918659A priority Critical patent/EP0654037B1/en
Priority to CA002141589A priority patent/CA2141589C/en
Priority to JP1994505559A priority patent/JP3561272B6/en
Priority to DE69324923T priority patent/DE69324923T2/en
Priority to HK98113194.0A priority patent/HK1011998B/en
Priority to US08/379,551 priority patent/US6653296B1/en
Application filed by Stichting Rega VZW, Gilead Sciences Inc filed Critical Stichting Rega VZW
Priority to DK93918659T priority patent/DK0654037T3/en
Publication of WO1994003467A2 publication Critical patent/WO1994003467A2/en
Publication of WO1994003467A3 publication Critical patent/WO1994003467A3/en
Publication of WO1994003467B1 publication Critical patent/WO1994003467B1/en
Anticipated expiration legal-status Critical
Priority to GR990401839T priority patent/GR3030754T3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6521—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Resolved enantiomers of formulae (IA) and (IB) wherein B is a purine or pyrimidine base or aza and/or deaza analogs thereof are useful in antiviral pharmaceutical compositions to treat retroviral infections.
PCT/US1993/007360 1992-08-05 1993-08-04 Antiretroviral enantiomeric nucleotide analogs Ceased WO1994003467A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DK93918659T DK0654037T3 (en) 1992-08-05 1993-08-04 Enantiomeric anti-retroviral nucleotide analogues
CA002141589A CA2141589C (en) 1992-08-05 1993-08-04 Antiretroviral enantiomeric nucleotide analogs
JP1994505559A JP3561272B6 (en) 1992-08-05 1993-08-04 Antiretroviral enantiomeric nucleotide analogues
DE69324923T DE69324923T2 (en) 1992-08-05 1993-08-04 Antiretroviral, enantiomeric nucleotide analogs
HK98113194.0A HK1011998B (en) 1992-08-05 1993-08-04 Antiretroviral enantiomeric nucleotide analogs
EP93918659A EP0654037B1 (en) 1992-08-05 1993-08-04 Antiretroviral enantiomeric nucleotide analogs
US08/379,551 US6653296B1 (en) 1992-08-05 1993-08-04 Antiretroviral enantiomeric nucleotide analogs
GR990401839T GR3030754T3 (en) 1992-08-05 1999-07-14 Antiretroviral enantiomeric nucleotide analogs.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/925,610 US6057305A (en) 1992-08-05 1992-08-05 Antiretroviral enantiomeric nucleotide analogs
US07/925,610 1992-08-05

Publications (3)

Publication Number Publication Date
WO1994003467A2 WO1994003467A2 (en) 1994-02-17
WO1994003467A3 true WO1994003467A3 (en) 1994-06-23
WO1994003467B1 WO1994003467B1 (en) 1994-07-21

Family

ID=25451994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/007360 Ceased WO1994003467A2 (en) 1992-08-05 1993-08-04 Antiretroviral enantiomeric nucleotide analogs

Country Status (12)

Country Link
US (3) US6057305A (en)
EP (2) EP0897917A1 (en)
JP (2) JP4083691B2 (en)
AT (1) ATE179983T1 (en)
CA (2) CA2141589C (en)
CZ (2) CZ290797B6 (en)
DE (1) DE69324923T2 (en)
DK (1) DK0654037T3 (en)
ES (1) ES2131116T3 (en)
GR (1) GR3030754T3 (en)
SG (1) SG47761A1 (en)
WO (1) WO1994003467A2 (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
CA2171868A1 (en) * 1993-09-17 1995-03-23 Petr Alexander Method for dosing therapeutic compounds
IT1270008B (en) * 1994-09-23 1997-04-16 Ist Superiore Sanita PURINIC AND 8-AZAPURINIC DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF AIDS
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
CA2224710A1 (en) * 1995-06-15 1997-01-03 Naoko Inoue Phosphonate nucleotide derivatives
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US5733788A (en) * 1996-07-26 1998-03-31 Gilead Sciences, Inc. PMPA preparation
DK0915894T3 (en) * 1996-07-26 2003-09-15 Gilead Sciences Inc nucleotide analogs
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
PT1243590E (en) * 1997-07-25 2005-05-31 Gilead Sciences Inc COMPOSITION OF NUCLEOTIC ANALOGS AND SYNTHESIS METHOD
DK1243590T3 (en) * 1997-07-25 2005-07-25 Gilead Sciences Inc Nucleotide analog composition and synthesis method
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
ATE413881T1 (en) 1997-08-08 2008-11-15 Celmed Oncology Usa Inc METHODS AND PREPARATIONS TO OVERCOME RESISTANCE TO BIOLOGICAL OR CHEMICAL THERAPIES
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
ES2172303T3 (en) 1998-01-23 2002-09-16 Newbiotics Inc THERAPEUTIC AGENTS OBTAINED BY ENZYMATIC CATALYSIS.
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
IL147749A0 (en) 1999-07-22 2002-08-14 Newbiotics Inc Methods for treating therapy-resistant tumors
AU2277201A (en) * 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Novel purines
HRP20030047B1 (en) 2000-07-21 2016-02-26 Gilead Sciences, Inc. MEDICINES THAT ARE PHOSPHONATE ANALYSIS OF NUCLEOTIDS AND THE METHODS OF SELECTION AND PREPARATION thereof
WO2002056832A2 (en) 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
BRPI0210746B8 (en) 2001-06-29 2021-05-25 Inst Of Organic Chemistry And Biochemistry Ascr 6-'2-(phosphonomethoxy)alkoxy-pyrimidine derivatives and their method of preparation
JP2005508924A (en) * 2001-08-30 2005-04-07 三菱ウェルファーマ株式会社 Antiviral agent
US7388002B2 (en) * 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
EA200400690A1 (en) * 2001-11-14 2005-06-30 Байокрист Фармасьютикалз, Инк. NUCLEOSIDES, THEIR PREPARATIONS AND THEIR APPLICATION AS VIRAL RNA POLYMERASE INHIBITORS
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
PT1583542E (en) 2003-01-14 2008-09-17 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
NZ543864A (en) 2003-06-16 2009-10-30 Leuven K U Res & Dev Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
UA93354C2 (en) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Topical antiviral formulations
US9512125B2 (en) * 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US8101745B2 (en) * 2004-12-16 2012-01-24 The Regents Of The University Of California Lung-targeted drugs
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP1879657A2 (en) * 2005-04-25 2008-01-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
ATE474560T1 (en) * 2005-12-14 2010-08-15 Cipla Ltd PHARMACEUTICAL COMBINATION OF NUCLEOTIDE AND NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (SUCH AS TENOFOVIR AND LAMIVUDINE) IN DIFFERENT PARTS OF THE DOSAGE UNIT
KR20150038395A (en) * 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Kinase antagonists
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US20080318904A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched tenofovir
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
BRPI0906473A8 (en) 2008-01-04 2016-02-10 Intellikine Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
TWI444384B (en) 2008-02-20 2014-07-11 Gilead Sciences Inc Nucleotide analogues and their use in the treatment of malignancies
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
KR20110065440A (en) * 2008-07-02 2011-06-15 아이데닉스 파마슈티칼스, 인코포레이티드 Compounds and pharmaceutical compositions for the treatment of viral infections
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
MX2011000216A (en) * 2008-07-08 2011-03-29 Intellikine Inc Kinase inhibitors and methods of use.
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (en) 2009-05-07 2015-10-07 インテリカイン， エルエルシー Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
TWI515000B (en) 2010-04-01 2016-01-01 伊迪尼克製藥公司 Compounds and pharmaceutical compositions for the treatment of viral infections
JP5951600B2 (en) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド Compounds, compositions and methods for kinase regulation
CN114010776A (en) 2010-06-09 2022-02-08 疫苗技术股份有限公司 Therapeutic immunization of HIV-infected persons for enhancing antiretroviral therapy
ES2551738T3 (en) 2010-06-11 2015-11-23 Gilead Sciences, Inc. Topical antiviral formulations for the prevention of HSV-2 transmission
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2012079035A1 (en) 2010-12-10 2012-06-14 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
ZA201103820B (en) 2010-12-13 2012-01-25 Laurus Labs Private Ltd Process for the preparation of tenofovir
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
TWI592411B (en) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 Combination of kinase inhibitors and uses thereof
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
ES2729824T3 (en) 2011-04-08 2019-11-06 Laurus Labs Ltd Solid forms of antiretroviral compounds, procedure for the preparation and pharmaceutical composition thereof
US20140073607A1 (en) 2011-05-10 2014-03-13 Okapi Sciences Nv Compounds for use in the treatment of feline retroviral infections
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (en) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc HETEROCYCLIC COMPOUNDS AND USES OF THEM
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
CN103917550B (en) 2011-11-16 2016-08-24 劳拉斯实验室私人有限公司 For the method preparing tenofovir
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN107312039B (en) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 A kind of preparation method of tenofovir prodrug
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
RU2702908C2 (en) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Treating malignant tumours using modulators of pi3-kinase isoforms
KR20150130355A (en) 2013-03-15 2015-11-23 더 리전트 오브 더 유니버시티 오브 캘리포니아 Acyclic nucleoside phosphonate diesters
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN104230934B (en) * 2013-06-08 2016-12-28 上海医药工业研究院 A kind of compound and its production and use
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103641857B (en) * 2013-12-20 2016-08-24 石药集团中诺药业（石家庄）有限公司 A kind of Novel tenofovir crystal form and preparation method thereof
TWI660965B (en) 2014-01-15 2019-06-01 美商基利科學股份有限公司 Solid forms of tenofovir
CN106456628A (en) 2014-03-19 2017-02-22 无限药品股份有限公司 Heterocyclic compounds for the treatment of PI3K‑γ-mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
MX377983B (en) 2014-09-15 2025-03-04 Univ California NUCLEOTIDE ANALOGUES.
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN114230571B (en) 2015-09-14 2025-07-08 无限药品股份有限公司 Solid forms of isoquinolinones, methods of making, compositions comprising, and methods of using the same
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
RU2020116571A (en) 2017-12-07 2021-11-22 Эмори Юниверсити N4-HYDROXYCYTIDINE AND DERIVATIVES AND RELATED ANTIVIRAL USES
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN115677774B (en) * 2021-07-23 2025-04-22 上海医药工业研究院有限公司 Phosphonate derivatives and preparation methods and uses thereof
KR20250052378A (en) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Compositions and dosage forms for the treatment of HPV infection and HPV-induced neoplasms

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
EP0009155A1 (en) * 1978-09-15 1980-04-02 Newport Pharmaceuticals International, Inc. 9-Hydroxyalkyl-purines, processes for preparing them and therapeutical composition containing the 9-hydroxyalkyl-purines as active ingredients
EP0130126A1 (en) * 1983-06-24 1985-01-02 Merck & Co. Inc. (S)-9-(2,3-dihydroxy-1-propoxymethyl) guanine and its acyl derivatives, their preparation and their application as antiherpetic agents
EP0253412A2 (en) * 1986-07-18 1988-01-20 Ceskoslovenska akademie ved N-Phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases, methods for their preparation and pharmaceutical compositions therefrom with antiviral activity
EP0292244A2 (en) * 1987-05-18 1988-11-23 Canon Kabushiki Kaisha Polymeric liquid crystal composition and liquid crystal device
EP0322815A2 (en) * 1987-12-25 1989-07-05 Daiichi Pharmaceutical Co., Ltd. Propoxybenzene derivatives and process for preparing the same
EP0368410A2 (en) * 1988-11-07 1990-05-16 Gist-Brocades N.V. Optically active benzoxazines and bezothiazines and a process for their stereospecific preparation
DE3906357A1 (en) * 1989-03-01 1990-09-06 Boehringer Mannheim Gmbh NEW ACYCLIC NUCLEOSIDE ANALOG, METHOD FOR THE PRODUCTION AND USE OF THESE COMPOUNDS AS ANTIVIRAL MEDICINAL PRODUCTS
EP0452935A1 (en) * 1990-04-20 1991-10-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB544419A (en) * 1940-01-08 1942-04-13 Union Special Machine Co Improvements in or relating to sewing machines
CS233665B1 (en) * 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
US4556727A (en) * 1984-07-18 1985-12-03 University Patents, Inc. Ferroelectric smectic liquid crystals
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
EP0264106B1 (en) * 1986-10-14 1994-03-16 Banyu Pharmaceutical Co., Ltd. 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use
IL84477A (en) * 1986-11-18 1995-12-08 Bristol Myers Squibb Co Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions containing them
US5650510A (en) * 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
JP2580205B2 (en) * 1987-10-21 1997-02-12 チッソ株式会社 Optically active-2-biphenylylpyridines
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
CZ285420B6 (en) * 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases, processes of their preparation and use
CS276072B6 (en) * 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF
CA2088363C (en) * 1990-08-10 2002-05-28 Purushotham Vemishetti Process for the preparation of nucleotides
DK0481214T3 (en) * 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prophylactic drugs of phosphonates
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
JPH10501217A (en) * 1994-05-31 1998-02-03 メディヴィル・アクチボラグ Stop after exposure to HIV

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
EP0009155A1 (en) * 1978-09-15 1980-04-02 Newport Pharmaceuticals International, Inc. 9-Hydroxyalkyl-purines, processes for preparing them and therapeutical composition containing the 9-hydroxyalkyl-purines as active ingredients
EP0130126A1 (en) * 1983-06-24 1985-01-02 Merck & Co. Inc. (S)-9-(2,3-dihydroxy-1-propoxymethyl) guanine and its acyl derivatives, their preparation and their application as antiherpetic agents
EP0253412A2 (en) * 1986-07-18 1988-01-20 Ceskoslovenska akademie ved N-Phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases, methods for their preparation and pharmaceutical compositions therefrom with antiviral activity
EP0292244A2 (en) * 1987-05-18 1988-11-23 Canon Kabushiki Kaisha Polymeric liquid crystal composition and liquid crystal device
EP0322815A2 (en) * 1987-12-25 1989-07-05 Daiichi Pharmaceutical Co., Ltd. Propoxybenzene derivatives and process for preparing the same
EP0368410A2 (en) * 1988-11-07 1990-05-16 Gist-Brocades N.V. Optically active benzoxazines and bezothiazines and a process for their stereospecific preparation
DE3906357A1 (en) * 1989-03-01 1990-09-06 Boehringer Mannheim Gmbh NEW ACYCLIC NUCLEOSIDE ANALOG, METHOD FOR THE PRODUCTION AND USE OF THESE COMPOUNDS AS ANTIVIRAL MEDICINAL PRODUCTS
EP0452935A1 (en) * 1990-04-20 1991-10-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY vol. no. 2 , 1993, pages 332-8 J.BALZARINI ' Differential Antiherpesvirus and Anti- virus Effects ' *
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY vol.2 no. 6, 1991, pages 329-336 P. CLAYETTE ' Anti-HIV activities of novel nucleoside analogues ' *
EUR. J. MED. CHEM.-- CHIM. THER. vol. 17, (1982) pages 569-576 L. COLLA ' Synthesis of aliphatic nucleoside analog with potential antiviral activity ' *
FUMIO SUGAWARA: "Stereoselective Synthesis of 1- and 2-O-alpha-D-Cellotriosyl-3-deoxy-2(R)- and 2(S)-glycerols Related to Rhynchosporoside", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 50, no. 9, 1986, TOKYO JP, pages 2261 - 2271 *
HOWARD J. SCHAEFFER: "Enzyme Inhibitors. VIII. Studies on the Mode of Binding of Some 6-Substituted 9-(Hydroxyalkyl)purines to Adenosine Deaminase", JOURNAL OF MEDICINAL CHEMISTRY, vol. 8, no. 4, 1965, WASHINGTON US, pages 502 - 506 *

Also Published As

Publication number Publication date
CA2574904A1 (en) 1994-02-17
CZ27295A3 (en) 1995-12-13
SG47761A1 (en) 1998-04-17
HK1011998A1 (en) 1999-07-23
JP2004189750A (en) 2004-07-08
JPH08503927A (en) 1996-04-30
JP3561272B2 (en) 2004-09-02
DK0654037T3 (en) 1999-11-01
ATE179983T1 (en) 1999-05-15
US6653296B1 (en) 2003-11-25
JP4083691B2 (en) 2008-04-30
ES2131116T3 (en) 1999-07-16
EP0654037B1 (en) 1999-05-12
EP0654037A1 (en) 1995-05-24
US6479673B1 (en) 2002-11-12
CA2574904C (en) 2009-06-16
GR3030754T3 (en) 1999-11-30
DE69324923D1 (en) 1999-06-17
EP0897917A1 (en) 1999-02-24
CZ293533B6 (en) 2004-05-12
CA2141589A1 (en) 1994-02-17
CZ290797B6 (en) 2002-10-16
DE69324923T2 (en) 1999-11-25
WO1994003467A2 (en) 1994-02-17
CA2141589C (en) 2007-04-17
US6057305A (en) 2000-05-02
JP2008120820A (en) 2008-05-29

Similar Documents

Publication Publication Date Title
CA2141589A1 (en) Antiretroviral enantiomeric nucleotide analogs
PA8483101A1 (en) CHEMICAL COMPOUNDS
IE901733L (en) Nucleoside analogs
IL84810A (en) Pharmaceutical antiviral compositions containing 1-beta-d-arabinofuranosyl-5-(1-alkynyl)cytosine and uracil derivatives thereof,some new such compounds and their preparation
AU4690989A (en) Antiviral cytosine and guanine derivatives
EP0222330A3 (en) N6-substituted-5'-oxidized adenosine analogs
PT85551A (en) Process for the preparation of antiviral pyrimidine derivatives and of pharmaceutical compositions containing the same
MY103801A (en) Dideoxydidehydrocarbocyclic nucleosides
DE69110854D1 (en) Antivirus derivatives of (phosphonomethoxy) methoxy purine / pyrimidine.
ZA931647B (en) Therapeutic nucleosides
AU619724B2 (en) Novel 9 - deazaguanines
ES8802363A1 (en) Nucleoside derivatives
AU6005586A (en) Antiviral compounds
AU2476388A (en) Therapeutic necleosides
ZA892284B (en) Novel fluorophosphonate nucleotide derivatives
EP0306597A3 (en) Antiviral nucleosides
AU2527688A (en) Artificial dna base pair analogues
EP0335770A3 (en) Novel fluorophosphonate nucleotide derivatives
GB8827339D0 (en) Antiviral compounds
GB9506644D0 (en) Preparation of nucleoside analogues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA CZ JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA CZ JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2141589

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 08379551

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PV1995-272

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1993918659

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993918659

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2001-529

Country of ref document: CZ

Ref document number: PV1995-272

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1993918659

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2001-529

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1995-272

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV2001-529

Country of ref document: CZ